196 related articles for article (PubMed ID: 22753276)
1. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
[TBL] [Abstract][Full Text] [Related]
2. Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer.
Scholz MC; Lam RY; Strum SB; Labarba DJ; Becker LK; Chang P; Farhoumand N; Jennrich RI
Clin Genitourin Cancer; 2011 Dec; 9(2):89-94. PubMed ID: 21993252
[TBL] [Abstract][Full Text] [Related]
3. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
4. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
Igdem S; Abacioglu U; Cetin I; Alco G; Akgun Z; Sengoz M; Bekiroglu N; Turkan S; Okkan S
J BUON; 2009; 14(4):629-34. PubMed ID: 20148454
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
6. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
8. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
10. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
11. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
13. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
14. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
16. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
Cooke EW; Shrieve DC; Tward JD
Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
[TBL] [Abstract][Full Text] [Related]
17. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
18. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer.
Divrik RT; Türkeri L; Şahin AF; Akdoğan B; Ateş F; Çal Ç; Baltacı S;
Urol Int; 2012; 88(1):25-33. PubMed ID: 22179324
[TBL] [Abstract][Full Text] [Related]
20. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]